Transthyretin amyloid cardiomyopathy (attr-CM)
Clinical trials for Transthyretin amyloid cardiomyopathy (attr-CM) explained in plain language.
Never miss a new study
Get alerted when new Transthyretin amyloid cardiomyopathy (attr-CM) trials appear
Sign up with your email to follow new studies for Transthyretin amyloid cardiomyopathy (attr-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can acoramidis improve daily life for heart amyloidosis patients?
Disease control Recruiting nowThis study follows 500 adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart condition caused by abnormal protein buildup. Participants take acoramidis as part of their usual care, and researchers collect data from hospitals and a European registry. The …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Bayer • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug aims to cut heart deaths in rare heart condition
Disease control Recruiting nowThis study tests an experimental drug called NNC6019-0001 in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 1,280 adults will receive either the drug or a placebo by IV, alongside their usual heart trea…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New heart drug acoramidis tested in Real-World setting
Disease control Recruiting nowThis observational study follows up to 2,000 adults with ATTR-CM, a serious heart condition, who are starting treatment with acoramidis as part of their normal care. Researchers will track patient characteristics, how the drug is used, and its effects on heart function and qualit…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Bayer • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC